Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better outcomes when treated with adjuvant anthracycline- plus taxane-based chemotherapy regimens compared with those receiving adjuvant taxane-based chemotherapy regimens alone, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.
UniQure trumpets mid-stage data for Huntington’s disease gene therapy
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
July 10, 2024